Artax Biopharma

First-in-class therapy for autoimmune disease

Artax is discovering small molecules that target Nck, a key cytoplasmic adapter protein, recently discovered to play a key role in T-cell signalling and activation.

The Artax approach has the potential to reduce auto-immunity without affecting the ability of the immune system to respond to an infectious challenge.

CEO  Joseph Lobacki

Advent Contact  Alan Walts

Advent invested in the Series B in 2015.
Private Companies
15 November 2022 in Artax Biopharma, Press Release, Private Companies

Artax Biopharma Expands Company’s Scientific Advisory Board

Press Release.   Company Welcomes James G. Krueger, M.D., Ph.D., and Ajay Nirula, M.D., Ph.D., Both Experts in T-Cell-Mediated Diseases. Cambridge, MA, November 15, 2022 - Artax Biopharma, Inc., a…
Read More
11 May 2022 in Artax Biopharma, Press Release, Private Companies

Artax Biopharma Closes Financing to Advance Clinical Stage First-in- Class Oral Immunomodulator to Treat T Cell-Mediated Diseases

Press Release.   Close of $26 Million Funds Immunomodulation Candidate AX-158 Development Adds New Investors Eli Lilly and Company and Sound Bioventures   Cambridge, MA, May 11, 2022 - Artax…
Read More
15 December 2021 in Artax Biopharma, Press Release, Private Companies

Artax Biopharma Announces First-in-Human Dosing in Phase 1 Clinical Trial for AX-158, Company’s First-in-Class Oral Immunomodulator to Treat T Cell-Mediated Diseases

Press Release.   The Phase 1 Trial, Expected to Conclude in 2022, Will Evaluate Safety, Exposure, and Pharmacokinetics of AX-158 in Healthy Volunteers AX-158, a Novel, Oral Small Molecule Immunomodulating…
Read More
13 July 2021 in Artax Biopharma, Press Release, Private Companies

Artax Biopharma Granted MHRA Clinical Trial Authorization for AX-158

Press Release.   Authorization Represents Start of Clinical Program for Company’s Global Platform of T Cell-Mediated Diseases Phase 1 Clinical Trial Expected to Start in Second Half of this Year…
Read More